Hepatocellular carcinoma (HCC) is a major worldwide public health concern. Despite recent advances, there has been little success in improving the survival of HCC patients. Due to advances in diagnostic modalities and the increasing incidence of chronic viral hepatitis and nonalcoholic fatty liver disease (NAFLD), both of which are well known risk factors of HCC, the prevalence of HCC is increasing in developed countries and it is expected that this trend will continue in the future.
Introduction and Global Importance Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer accounting for 7.5% and 3.5% of all cancers among men and women, respectively 1 and accounts for half a million deaths per year. 2, 3 The distribution of HCC varies widely.
In terms of global prevalence, HCC ranks as the eighth most common cancer, sixth among men and eleventh among women. 4 In some countries, such as China, HCC ranks as the second most common internal malignancy. 5, 6 Primary liver cancer is more prevalent among men than women.
The gender-specific age-adjusted incident rate (AAIR) ratio ranges from 1.3 to 3.6 worldwide. 1 In high risk areas, liver cancer incidence rates increase after 20 years of age and peak at about age 50. In most European countries and America, HCC incidence peaks at 75 years of age. 7 The global difference in AAIR reflects differences in the natural history of the hepatitis B virus (HBV), the most common cause of liver cancer in Asian and African countries and the hepatitis C virus (HCV), the most common cause of HCC in regions with a low prevalence of HBV (e.g., America, Northern Europe and Australia). 
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Although HCC is more prevalent in Asian and African nations, there is evidence to conclude that the incidence of HCC is rising in developed countries. During the last two decades, an increase in HCC incidence has been reported from Australia, 8 France, 9 the United Kingdom, 10 Japan 11 and North America. 7 Evidence suggests that the increased incidence of HCC in developed countries is not solely attributable to more accurate and earlier diagnosis or to an increase in immigration from high prevalence regions.
HCC is a disease that is relatively insensitive to chemotherapy and/or radiotherapy. Further, given that the liver is usually compromised in the majority of persons who develop the tumor, it is associated with an extremely poor prognosis. For this reason, mortality from HCC almost equals its incidence.
There were an estimated 383,593 deaths among men and 164,961 deaths among women attributable to HCC for the year 2000, which is quite close to the HCC incidence during the same time period. 7 An increase in the mortality rate of liver cancer among men has recently been reported in some developed countries including the United States, Japan, Scotland, France and Italy.
12,13
The mortality rate among women however was unchanged. 7 These data suggest that primary liver cancer is an important global public health problem. In spite of vaccination programs against HBV in many countries, the incidence and mortality from HCC is increasing, particularly in western countries where the prevalence of HBV is low.
Burden of Liver Cancer in the Middle east
In Middle Eastern countries, liver cancer is a major concern among men, especially in certain countries such as Egypt and Saudi Arabia, and to a lesser extent in other countries of this region.
Recent reports demonstrate that the incidence of HCC has increased sharply in the last 5-10 years, [14] [15] [16] with an especially high incidence in Egypt 17 ( Figure 1 ). However, in general, HCC is less prevalent in the Middle East compared to high incidence countries.
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The incidence varies significantly among different districts and countries 18, 19 (Table 1) .
The prevalence of HCC is high in the Nile Delta area. HCC is also more common among males, rural residents and farmers which it is believed that pollution due to insecticides might be one of the risk factors. 20 In Iran, HCC is the 16 th most prevalent cancer.
21,22
Risk Factors for HCC HCC is one of the few cancers with clearly defined major risk factors. These include chronic viral hepatitis, alcohol consumption, NAFLD, aflatoxin ingestion, exposure to inorganic arsenic through Epidemiologic studies have demonstrated a strong association between CHB and HCC. Thus, the incidence of HCC increases parallel the prevalence of HBsAg in all geographic areas.
30 Generally, in patients who are infected in the first year or two year of life, the interval between initiation of chronic infection and the peak incidence of HCC is 30-50 years.
31,32
The relative risk for the development of HCC in cohort studies in which HBV infected patients were followed until HCC developed has been reported to be 7-100 times higher than in those without infection.
33-35
The exact level of risk depends on the severity and activity of the resultant liver disease as well as the presence or absence of other pro-oncogenic risk factors.
There are two possible pathways for the involvement of HBV in the development of liver cancer. In the first, the HBV genome may directly participate in causing genetic changes in the host genome that lead to hepatocarcinogenesis. In the second, HCC develops in HBV-related cirrhosis.
Mutations in the HBV genotype are also found to be associated with HCC occurrence. Two important groups of predisposing mutations have been described: those occurring in the pre-core region and those occurring in the basal core promoter (BCP).
The dominant pre-core variant is a point mutation from G to A at nucleotide (nt) 1896 (G1896A). This terminates translation of the pre-core/core protein and interrupts HBeAg synthesis. 36, 37 The most common BCP variants are at nucleotide 1762 (A1762T) and 1764 (G1764A).
These variants reduce the pre-core RNA level and consequently reduces HBeAg production at a transcriptional level. 36, 37 Core promoter and BCP mutants are associated with severe and advanced liver disease.
37-41
PreS deletion of HBV has recently been shown to be associated with liver disease progression and HCC development in HBV carriers. PreS mutant viruses lack potent B-and T cell epitopes which normally exist in the preS region. This variant could escape from immune system surveillance. Subsequently, ER stress not only can induce oxidative DNA damage and genomic instability, but also can induce proliferation-related signal pathways in the hepatocytes which may progress to tumor formation. 42 Thus, the observed difference in fraction of HCC that is attributable to HBV in different regions may be due to difference in the influence of the HBV genotype on the outcome of CHB.
HBV in the Middle east
In Middle Eastern countries, the prevalence of HBV varies according to geographic region. Similar to the world distribution of HBV, countries of this region fall within all three groups of low, intermediate and high endemic areas of HBV.
The HBV prevalence ranges from 0.8 to 7% in Iran, 2 to 5% in the UAE, 2.3 to 10% in Oman, 2.6 to 10% in Jordan, 2 to 6% in Libyan Arab Jamahiriya, 4 to 5% in Iraq, 5 to 6% in Palestine, 6.5% in Tunisia, 5 to 10% in Turkey, 7.4 to 17% in Saudi Arabia, 12.7 to 18.5% in Yemen and 16 to 20% in Sudan. [43] [44] [45] [46] In Lebanon, the prevalence of HBV in blood donors is 1-2%. 47, 48 In Turkey, HBV is endemic. The seropositivity rate for HBsAg in the general population in Turkey is 5-10%.
Studies from Iran, Pakistan, Turkey, Egypt, Saudi Arabia, Jordan and Yemen provide evidence to show that the dominant genotype of HBV in most Middle Eastern countries is genotype D. [49] [50] [51] [52] [53] [54] It seems that certain mutations in the genome of HBV are associated with the severity of hepatitis B chronic infections and the natural history of HCC. In Iran, a country with intermediate endemicity for HBV infection, approximately 35% of the population have been exposed to the virus while about 3% have chronic infection. 55, 56 Although HBV is the most common etiological agent for cirrhosis in Iran with evidence of previous exposure in up to 30% of cases, 57 The results of this study showed that the prevalence of A1762T-G1764A mutation was higher in patients with advanced liver disease (cirrhosis and HCC) and was also associated with higher ALT level and viral load. 49 On the other hand, we have found the G1757A substitution in this part of HBV gene which seems to be protective, being 90% less frequent among patients with cirrhosis and HCC (p=0.001).
In addition, other factors might be responsible for a low prevalence of HCC in Iran and other Middle Eastern countries. These include very low consumption of alcohol, lower pathologic-based diagnosis of HCC and perhaps lower survival of cirrhotic patients.
In conclusion, HBV genotype may influence the severity of CHB disease and development of HCC. Further research however is required to clarify the role of virus genotype and the associated mutations to the progression of liver disease and HCC. Before the introduction of screening tests, blood transfusion and injection drug use (IDU) were the main risk factors for HCV acquisition, being identified in 60-80% of cases. After the implementation of routine blood donor screening however, injection drug use is the main risk factor.
Chronic Hepattis C
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Phylogenetic analysis of the nucleotide sequences derived from HCV has identified six major genotypes of the virus. Table 3 demonstrates the global distribution pattern of HCV infection by genotype.
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HCV infection causes acute and chronic liver disease. Unlike CHB, the majority (70%) of patients infected with HCV, irrespective of their age of acquisition, will progress to chronic disease.
The exact pathogenesis of hepatic injury is not well understood in chronic HCV. It has been suggested that HCV is not cytopathic to hepatocytes and that the immune response, especially cytotoxic T cell responses against HCV-infected hepatocytes, is the main cause of liver cell injury, fibrosis, cirrhosis and eventually HCC. Cytokines such as interferon gamma and tumor necrosis factor alpha released from activated lymphocytes may play important roles in the pathogenesis of liver injury associated with chronic HCV infection (CHC).
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Cirrhosis and HCC are the most serious complications of CHC.
72 Donato et al. 73 noted that the risk of HCC increased 17-fold among HCV-infected patients compared with anti-HCV negative controls. Unlike CHB, HCV-related HCC always occurs in older persons, and nearly all cases are associated with advanced hepatic fibrosis or cirrhosis.
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The incidence of liver cancer in HCV patients with cirrhosis is 3 to 10% per annum. The incidence in Western countries is 3-5% per year, but higher in Asian nations.
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Results of a study in Japan revealed that the incidence of HCC among those with CHC and cirrhosis was approximately 10%, which was higher than seen for CHB infection (4%).
76 Shiratori et al. 77 analyzed the characteristics of 205 HCC cases from Japan and noted that CHC-associated HCC occurred in the presence of more severe liver disease than in CHB-associated HCC.
These data suggest that HBV is more oncogenic than HCV with the latter being associated with the development of HCC usually only in the presence of advanced liver disease.
HCV in the Middle east
The World Health Organization estimates that there are at least 21.3 million HCV carriers in the Eastern Mediterranean countries, which is close to the number of carriers estimated in the Americas and Europe combined.
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The prevalence of HCV infection in Middle Eastern countries varies geographically. This prevalence is 0.5-1% in Iran, 6.8% in Saudi Arabia, 4.2% in Yemen, 4.4% in Sudan, 5% in Pakistan, 0.1-0.6% in Lebanon, and 1.5% in Turkey. 6, 47, 48, [79] [80] [81] [82] [83] [84] The highest prevalence belongs to Egypt with 22%. 82, 85 In a population-based study in Iran done by Merat et al., the prevalence of HCV in Iran was 0.3%, 1.6% and 1.0% in Tehran, Hormozgan, and Golestan provinces, respectively.
86 It has been well documented that the prevalence rate of HCV infection in Egypt is among Table 4 . 103 The accumulated data show that there are two main patterns for the distribution of HCV genotypes: one is peculiar to the Arab countries (with the exception of Jordan) where genotype 4 predominates, while the other pattern is characteristic of the nonArab countries (Turkey, Pakistan and Iran) where genotype 1 predominates. Although varying prevalence of genotype 4 have been reported from Arab countries, it is noteworthy that genotype 4 is quasiexclusive (91%) in Egypt which is also a North African country. 79, 94, 97 Based on only one known study in Jordan, 1a is the dominant subtype (40%) followed by 1b (33.3%) and genotype 4 (26.6%).
91
In Turkey 92,93 subtype 1b is the dominant subtype (>70%) followed by 1a, which is similar to the pattern seen in Eastern and Southern Europe.
104,105
Subtype 3a is the most common subtype in Iran followed by 1a, 1b and 4.
98
Results from the limited number of clinical trials on the treatment of chronic HCV genotype 4 using peginterferon alfa-2b in combination with ribavirin are encouraging. [106] [107] [108] [109] [110] However, efforts to develop more effective antiviral therapies and the establishment of an effective HCV vaccine remain the largest challenges for the near future.
HBV and HCV Co-infection
Co-infection with HBV and HCV is associated with a higher risk for developing HCC than either infection alone. In an Australian case-control study, Dutta et al. 111 have demonstrated that the risk of developing HCC in HCV-infected patients was 5.5-fold higher if a patient was anti-HBc positive.
Likewise, in a meta-analysis of 32 case-control studies, the odds ratio for the development to HCC was 165 for the co-infection with HBV and HCV (versus no infection), 23 for isolated infection with HBV, and 17 for isolated infection with HCV (both versus no infection). (Table 5) .
In Lebanon, HCC is a relatively rare cancer, ranking 14th among both males and females with an age standardized rate of 3.5 and 2.2 per 100 000, respectively.
23 Results of studies in this country reveal that most HCC patients in Lebanon have HBV-related liver cirrhosis, accounting for nearly two thirds of the subjects followed by HCV, and alcohol abuse.
Interestingly, there were no cases of non-alcoholic steatohepatitis-or cryptogenic cirrhosis-related HCC in this study population.
112 Of note, the HBV and HCV carrier state in Lebanese blood donors is 1%-2% and 0.1%-0.6%, respectively. In Turkey, HBV infection was found to be the leading cause of HCC, followed by HCV infection and alcoholic liver disease. 45 Hepatitis B, hepatitis C and excessive alcohol intake were detected in 56%, 23.2% and 15.9% of Turkish HCC patients, respectively.
45
In Saudi Arabia, a study by Altaf et al. has demonstrated that HBsAg and HCVAb were positive in 23% and 53% of chronic liver disease cases, respectively.
113 HCV plays a major role in the epidemiology of HCC in Saudi Arabia where 39.5% of patients are anti-HCV antibody positive.
79 This is in contrast to an overall HCV seroprevalence of 1.1% to 2.9% among Saudi-blood donors.
79
This might be attributed to some factors related to either the virus or host in the Saudi population.
In Iran, a study by Fani et al. has shown the prevalence of HCC to be approximately 3.1% in HBV and HCV chronic carriers combined, and the estimated annual incidence of HCC is 1.02 (95% CI: 0.5-1.8). The authors have found no association between viral type and HCC. 114 Lastly, recent studies have demonstrated that unlike other countries of the Middle East, the attributable fraction of HCC due to HCV is quite high in Egypt and Saudi Arabia, and HBV and environmental risk factors play a minor role in the incidence of HCC. 82, 85 In spite of vaccination against HBV, this virus will remain one the major etiologies for HCC in next 40 years. However the role of HBV infection as an etiology of HCC would become negligible during the second half of the 21st century.
As no vaccination is available for HCV, further investigation of the risk factors and modes of transmission of HCV are required to reduce infection rates and to prevent future cases of HCC. Sampling of markers of HBV and HCV exposure through population-based studies can provide useful data in designing cost-effective and country-specific intervention strategies to reduce HCC.
Further, the development of early detection markers is a vital missing component in strategies to reduce HCC mortality.
115 Molecular epidemiology studies may provide a better understanding of the temporal occurrence of genetic and epigenetic alterations in the natural history of liver carcinogenesis.
116-118
In conclusion HCC is not as common in the Middle East as it is in East Asia. The rising incidence of HCV infection along with the pandemic of obesity and diabetes mellitus will become major risk factors for HCC in the future. Further studies to develop an evidence-based strategy to prevent HCC in Middle Eastern countries are necessary. 
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